CAR T and Bispecific Agents in Hematologic Malignancies
Emerging perspectives on the current and potential roles of bispecific agents and CAR T in myeloma, leukemia, and lymphomas: application, investigational approaches, and management of toxicities
September 8, 2020
FACULTY CHAIR
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center Houston, TX, USA
Faculty Members
Justin Kline, MD
Jae Park, MD
Sattva Neelapu, MD
Daniel DeAngelo, MD, PhD
Stephen Schuster, MD
Timothy Fenske, MD, MS
Joshua Brody, MD
Nina Shah, MD
Julio Chavez, MD
Michel Sadelain, MD, PhD
Krina K. Patel, MD
REPORT TOPICS INCLUDE
- The Nature of Bispecific Agents and Application in Leukemias
- Investigational Approaches for Bispecific Agents
- CAR T in DLBCL, MCL and FL, ALL, and MM
- Managing Toxicities of Bispecifics and CAR T Cells
